OBJECTIVE: To describe a case of moderate ovarian hyperstimulation syndrome (OHSS) that was treated with high dose cabergoline. DESIGN: Case report. SETTING: Private assisted reproduction center. PATIENT(S): A 29-year-old woman who developed early moderate OHSS despite preventive cabergoline administration (0.5 mg/day) following controlled ovarian hyperstimulation for IVF treatment. INTERVENTION(S): Cabergoline dose was increased to 1 mg/day upon diagnosis of OHSS on the second day after oocyte collection and embryo transfer was postponed to the fifth day after oocyte collection. MAIN OUTCOME MEASURE(S): Resolution of OHSS and achievement of healthy live birth. RESULT(S): OHSS resolved rapidly despite occurrence of pregnancy and patient delivered a healthy boy at term. CONCLUSION(S): The higher cabergoline dose might have prevented an increase in the severity of OHSS and its prolongation following occurrence of pregnancy. Randomized controlled trials assessing the efficacy and safety of different doses and durations of cabergoline administration in both prophylactic and therapeutic settings are required.
OBJECTIVE: To describe a case of moderate ovarian hyperstimulation syndrome (OHSS) that was treated with high dose cabergoline. DESIGN: Case report. SETTING: Private assisted reproduction center. PATIENT(S): A 29-year-old woman who developed early moderate OHSS despite preventive cabergoline administration (0.5 mg/day) following controlled ovarian hyperstimulation for IVF treatment. INTERVENTION(S): Cabergoline dose was increased to 1 mg/day upon diagnosis of OHSS on the second day after oocyte collection and embryo transfer was postponed to the fifth day after oocyte collection. MAIN OUTCOME MEASURE(S): Resolution of OHSS and achievement of healthy live birth. RESULT(S): OHSS resolved rapidly despite occurrence of pregnancy and patient delivered a healthy boy at term. CONCLUSION(S): The higher cabergoline dose might have prevented an increase in the severity of OHSS and its prolongation following occurrence of pregnancy. Randomized controlled trials assessing the efficacy and safety of different doses and durations of cabergoline administration in both prophylactic and therapeutic settings are required.